pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2012-0-1-88-94pulmo-23Research ArticleОБЗОРЫREVIEWХроническая легочная гипертония и система оксида азотаChronic pulmonary hypertension and nitric oxideМарковХ. М.MarkovKh. M.

д. м. н., проф.

119991, Москва, Ломоносовский пр-т, 2. Тел.: (499) 241-53-89.

ФГБУ "Научный центр здоровья детей" РАМНRussian Federation201228022012018894Copyright © Марков Х.М., 20122012Марков Х.М.Markov K.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/23

Хроническая легочная гипертония и система оксида азота.

Chronic pulmonary hypertension and nitric oxide.

легочная гипертониясистема оксида азотадефицит оксида азотафармакотерапияpulmonary hypertensionnitric oxidenitric oxide deficiencypharmacotherapyReferencesRomberg E. Uber sclerose der lungenarterie. Dtsch. Arch. Klin. Med. 1891; 48: 197–206.Romberg E. Uber sclerose der lungenarterie. Dtsch. Arch. Klin. Med. 1891; 48: 197–206.Coggion M.P., Bloch K. Nitric oxide in the pulmonary vasculature. Arterioscler. Thromb. Vasc. Biol. 2007; 27: 1877–1885.Coggion M.P., Bloch K. Nitric oxide in the pulmonary vasculature. Arterioscler. Thromb. Vasc. Biol. 2007; 27: 1877–1885.Steudel O.V., Scherrer-Grosbi M., Bloch K.D. et al. Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of eNOS. J. Clin. Invest. 1998; 101: 2468–2477.Steudel O.V., Scherrer-Grosbi M., Bloch K.D. et al. Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of eNOS. J. Clin. Invest. 1998; 101: 2468–2477.Fagan K.A., Nyler R.C., Sato K. et al. Relative contribution of eNOS, iNOS and nNOS to (tone) in the marine pulmonary circulation. Am. J. Physiol. 1999; 277: L472–L478.Fagan K.A., Nyler R.C., Sato K. et al. Relative contribution of eNOS, iNOS and nNOS to (tone) in the marine pulmonary circulation. Am. J. Physiol. 1999; 277: L472–L478.Hampl V., Herget J. Role of NO in the pathogenesis of pulmonary hypertension. Physiol. Rev. 2000; 80: 1337–1372.Hampl V., Herget J. Role of NO in the pathogenesis of pulmonary hypertension. Physiol. Rev. 2000; 80: 1337–1372.Moutgil R., Michelakis E.D., Archer S.L. Hypoxic pulmonary vasoconstriction. J. Appl. Physiol. 2005; 98: 390–403.Moutgil R., Michelakis E.D., Archer S.L. Hypoxic pulmonary vasoconstriction. J. Appl. Physiol. 2005; 98: 390–403.Murata T., Sato K., Hori M. et al. Decreased eNOS activity resulting from abnormal interaction between eNOS and its regulatory protein in hyxoxia-induced oulmonary hypertension. J. Biol. Chem. 2002; 277: 1485–1492.Murata T., Sato K., Hori M. et al. Decreased eNOS activity resulting from abnormal interaction between eNOS and its regulatory protein in hyxoxia-induced oulmonary hypertension. J. Biol. Chem. 2002; 277: 1485–1492.Naage J., Valen G. Preconditioning and cardiac surgery. Ann. Thorac. Surg. 2003; 75: S709–S714.Naage J., Valen G. Preconditioning and cardiac surgery. Ann. Thorac. Surg. 2003; 75: S709–S714.Kielstein J.T., Bode-Boger S.M., Hesse G. et al. Asymmetric dimethylarginine in idiopatic pulmonary arterial hypertension. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 1414–1418.Kielstein J.T., Bode-Boger S.M., Hesse G. et al. Asymmetric dimethylarginine in idiopatic pulmonary arterial hypertension. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 1414–1418.Leiper J., Nandi M., Torondel B. et al. Disrubtion of methylarginine metabolism impairs vascular homeostasis. Nature Med. 2007; 13: 198–203.Leiper J., Nandi M., Torondel B. et al. Disrubtion of methylarginine metabolism impairs vascular homeostasis. Nature Med. 2007; 13: 198–203.Khoo L.P., Zhao L., Alp N.J. et al. Role of endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation 2008; 111: 2126–2133.Khoo L.P., Zhao L., Alp N.J. et al. Role of endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation 2008; 111: 2126–2133.Giaid A., Salch D. Reduced expression of eNOS in the lung of patients with pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2005; 172: 352–357.Giaid A., Salch D. Reduced expression of eNOS in the lung of patients with pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2005; 172: 352–357.Zeiher A.M., Schachinger V., Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995; 92: 1094–1100.Zeiher A.M., Schachinger V., Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995; 92: 1094–1100.Barbera J.A., Peinado V.I., Santos S. et al. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am. J. Respir. Crit. Care Med. 2001; 164 (4): 709–713.Barbera J.A., Peinado V.I., Santos S. et al. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am. J. Respir. Crit. Care Med. 2001; 164 (4): 709–713.Assreuy J., Cunha F.Q., Liew F.Y., Moncada S. Feedback inhibition of NOS-activity by nitric oxide. Br. J. Pharmacol. 1993; 108: 833–837.Assreuy J., Cunha F.Q., Liew F.Y., Moncada S. Feedback inhibition of NOS-activity by nitric oxide. Br. J. Pharmacol. 1993; 108: 833–837.Su Y., Han W., Giraldo C. et al. Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells. Am. J. Respir. Cell Mol. Biol. 1998; 19: 819–825.Su Y., Han W., Giraldo C. et al. Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells. Am. J. Respir. Cell Mol. Biol. 1998; 19: 819–825.Griffits M.J.D., Evans T.W. Inhaled NO therapy in adults. N. Engl. J. Med. 2005; 353: 2683–2695.Griffits M.J.D., Evans T.W. Inhaled NO therapy in adults. N. Engl. J. Med. 2005; 353: 2683–2695.Ishinose F., Roberts J.D., Zapol W.M. Inhaled NO: a selective pulmonary vasodilator current uses and therapeutic potential. Circulation 2004; 109: 3106–3111.Ishinose F., Roberts J.D., Zapol W.M. Inhaled NO: a selective pulmonary vasodilator current uses and therapeutic potential. Circulation 2004; 109: 3106–3111.Sitbon O., Brenot F., Denjean A. et al. Inhaled NO as a screening vasodilator agent in primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 1995; 151: 384–389.Sitbon O., Brenot F., Denjean A. et al. Inhaled NO as a screening vasodilator agent in primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 1995; 151: 384–389.Taylor R.W., Zimmerman J.L., Dellinger R.P. et al. Low-dose inhaled NO in patients with acute lung injury: a randomized controlled trial. J.A.M.A. 2004; 291: 1603–1609.Taylor R.W., Zimmerman J.L., Dellinger R.P. et al. Low-dose inhaled NO in patients with acute lung injury: a randomized controlled trial. J.A.M.A. 2004; 291: 1603–1609.Brandler M.D., Powell S.C., Craig D.M. et al. A novel inhaled organic nitrate that affects pulmonary vascular tone in a piglet model of hypoxia-induced pulmonary hypertension. Pediatr. Res. 2005; 58: 531–536.Brandler M.D., Powell S.C., Craig D.M. et al. A novel inhaled organic nitrate that affects pulmonary vascular tone in a piglet model of hypoxia-induced pulmonary hypertension. Pediatr. Res. 2005; 58: 531–536.Hanter C.J., Dejam A., Blood A.B. et al. Inhaled nebulized nitrit is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nature Med. 2004; 10: 1122–1127.Hanter C.J., Dejam A., Blood A.B. et al. Inhaled nebulized nitrit is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nature Med. 2004; 10: 1122–1127.Michelakis E.D. Soluble guanylate cyclase as a potential therapy for pulmonary arterial hypertension. Eur. Respir. J. 2009; 33 (4): 717–721.Michelakis E.D. Soluble guanylate cyclase as a potential therapy for pulmonary arterial hypertension. Eur. Respir. J. 2009; 33 (4): 717–721.Wilkens H., Guth A., Konig J. et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary circulation. Circulation 2001; 104: 1218–1222.Wilkens H., Guth A., Konig J. et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary circulation. Circulation 2001; 104: 1218–1222.Fesler P., Pagnamenta A., Rondelet B. et al. Effects of sildenafil on hypoxic pulmonary vascular function in dogs. J. Appl. Physiol. 2006; 101: 1085–1090.Fesler P., Pagnamenta A., Rondelet B. et al. Effects of sildenafil on hypoxic pulmonary vascular function in dogs. J. Appl. Physiol. 2006; 101: 1085–1090.Mermuly R.T., Kreisselmeier K.P., Chofrani H.A. et al. Chronic sildenafil treatment inhibits monocrotalineinduced pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2004; 169: 39–45.Mermuly R.T., Kreisselmeier K.P., Chofrani H.A. et al. Chronic sildenafil treatment inhibits monocrotalineinduced pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2004; 169: 39–45.Mondelet B., Kerbanl F., Fireston L. et al. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effect of sildenafil therapie. Circulation 2004; 110: 2220–2225.Mondelet B., Kerbanl F., Fireston L. et al. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effect of sildenafil therapie. Circulation 2004; 110: 2220–2225.Ghofrani H.A., Schermuly R.T., Rose F. et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2003; 167: 1139–1141.Ghofrani H.A., Schermuly R.T., Rose F. et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2003; 167: 1139–1141.Ghofrani H.A., Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur. Respir. Rev. 2009; 18: 35–41.Ghofrani H.A., Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur. Respir. Rev. 2009; 18: 35–41.Grimminger F., Weimann G., Frey R. et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur. Respir. J. 2009; 33: 785–792.Grimminger F., Weimann G., Frey R. et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur. Respir. J. 2009; 33: 785–792.Girgis R.E., Zhan X., Garcia J.G.N. et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am. J. Physiol. 2003; 285: H938–H945.Girgis R.E., Zhan X., Garcia J.G.N. et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am. J. Physiol. 2003; 285: H938–H945.Murata T., Kinoshita K., Hori M. et al. Statin protects eNOS activity in hypoxia-induced pulmonary hypertension. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2335–2342.Murata T., Kinoshita K., Hori M. et al. Statin protects eNOS activity in hypoxia-induced pulmonary hypertension. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2335–2342.Champion H.C., Bivalacqwa T.J., Greenberg S.S. et al. Adenoviral gene transfer of eNOS partially restores normal pulmonary arterial pressure in eNOS-deficient micc. Proc. Natl Acad. Sci. USA 2002; 92: 13248–13253.Champion H.C., Bivalacqwa T.J., Greenberg S.S. et al. Adenoviral gene transfer of eNOS partially restores normal pulmonary arterial pressure in eNOS-deficient micc. Proc. Natl Acad. Sci. USA 2002; 92: 13248–13253.Sata M. Role of circulating vascular progenitors in angiogenesis vascular healing and pulmonary hypertension: lessons from animal models. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 1008–1014.Sata M. Role of circulating vascular progenitors in angiogenesis vascular healing and pulmonary hypertension: lessons from animal models. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 1008–1014.Zhao Y.D., Courtman D.W., Deng Y. et al. Rescue of pulmonary hypertension using endothelial-like progenitor cells. Circ. Res. 2005; 96: 442–450.Zhao Y.D., Courtman D.W., Deng Y. et al. Rescue of pulmonary hypertension using endothelial-like progenitor cells. Circ. Res. 2005; 96: 442–450.Kanki-Horimoto S., Horimoto H., Mieno S. et al. Implantation of mesenchimal stem cell overexpressing eNOS improves right ventricular impairments caused by pulmonary hypertension. Circulation 2006; 114: 181–185.Kanki-Horimoto S., Horimoto H., Mieno S. et al. Implantation of mesenchimal stem cell overexpressing eNOS improves right ventricular impairments caused by pulmonary hypertension. Circulation 2006; 114: 181–185.Russwurm M., Mergia E., Mulleshausen F. et al. Inhibition of deactivation of NO-sensitive guanylyl cyclase account for the sensitizing effect of YC-1. J. Biol. Chem. 2002; 277: 24883–24888.Russwurm M., Mergia E., Mulleshausen F. et al. Inhibition of deactivation of NO-sensitive guanylyl cyclase account for the sensitizing effect of YC-1. J. Biol. Chem. 2002; 277: 24883–24888.

The authors declare that there are no conflicts of interest present.